Introduction 44
Dipeptidyl peptidase IV (DPP-IV) is an ubiquitous enzyme which is involved in the 45 cleavage of incretin hormones such as glucose dependent insulinotropic polypeptide (GIP) 46 and glucagon-like peptide-1 (GLP-1). Following food intake, the incretins can modulate 47 insulin synthesis and secretion (Juillerat-Jeanneret, 2014) . Their cleavage results in a 48 reduction in the circulating level of their active form, which in turn leads to a decrease in 49 insulin secretion from pancreatic beta cells. DPP-IV inhibition is currently being used as a 50 therapeutic strategy in the treatment of Type 2 diabetes (Juillerat-Jeanneret, 2014) . Several 51 DPP-IV inhibitory drugs, also known as gliptins, have been developed. These drugs generally 52 have a high DPP-IV inhibitory potency, with half maximum inhibitory concentration (IC 50 ) 53 values of several nM (Nongonierma & FitzGerald, 2013b; Sortino, Sinagra & Canonico, 54 2013) . It has been shown that a wide range of dietary protein hydrolysates can inhibit DPP-IV 55 (Connolly, Piggott & FitzGerald, 2014; Harnedy & FitzGerald, 2013; Hatanaka et al., 2012; 56 Huang, Jao, Ho & Hsu, 2012; Li-Chan, Hunag, Jao, Ho & Hsu, 2012; Nongonierma & 57 FitzGerald, 2013a; Uchida, Ohshiba & Mogami, 2011; Uenishi, Kabuki, Seto, Serizawa & 58 Nakajima, 2012; Velarde-Salcedo et al., 2013) . More particularly, milk protein hydrolysates 59 have proven to be a good source of DPP-IV inhibitory peptides (Lacroix & Li-Chan, 2013; 60 Lacroix & Li-Chan, 2014a; Nongonierma & FitzGerald, 2013a; Silveira, Martínez-Maqueda, 61 Recio & Hernández- Ledesma, 2013; Tulipano, Sibilia, Caroli & Cocchi, 2011) . Milk protein-62 derived peptide sequences and free amino acids have been shown to possess a wide range of 63 DPP-IV inhibitory potencies (Nongonierma & FitzGerald, 2013a , 2013c , 2013d , 2014 64 Nongonierma, Mooney, Shields & FitzGerald, 2013; Silveira et al., 2013; Tulipano et al., 65 2011; Uchida et al., 2011; Uenishi et al., 2012) . DDP-IV inhibitory peptide sequences 66 originating from rice (Hatanaka et al., 2012) , amaranth (Velarde-Salcedo et al., 2013) , tuna 67 cooking juice (Huang et al., 2012) , a dried-cured ham water soluble extract (Gallego, Aristoy 68 & Toldrá, 2014) , salmon (Li-Chan et al., 2012) and porcine skin gelatin (Hsu, Tung, Huang 69 & Jao, 2013) have also been reported. However, milk appears to be the main dietary protein 70 source from which DPP-IV inhibitory peptides have been identified to date. 71 Different in silico approaches have been utilised to predict the potential of dietary proteins 72 to act as a source of DPP-IV inhibitory peptides (Lacroix & Li-Chan, 2012 ). These studies 73 have shown that proteins such as cow's milk, bovine and salmon collagen (Lacroix & Li-74 Chan, 2012; Udenigwe, Gong & Wu, 2013) and the small subunit of sorghum ribulose 75 bisphosphate carboxylase (RuBisCo) (Udenigwe et al., 2013) were good sources of DPP-IV 76 inhibitory peptide sequences. These in silico studies were based on calculation of the 77 frequency of occurrence of DPP-IV inhibitory peptides which, corresponds to the number of 78 DPP-IV inhibitory peptides found within a dietary protein divided by the protein length (total 79 number of amino acid residues). These frequency of occurrence values, however, considered 80 that all DPP-IV inhibitory peptide sequences may be simultaneously released from the 81 relevant dietary protein and that they are equivalent in terms of their bioactive properties. 82
However, neither the potency of the peptides nor the overlapping amino acid residues (≥ 1 83 common amino acid residue) for the different DPP-IV inhibitory peptides were taken into 84 account in these in silico analyses. Furthermore, new DPP-IV inhibitory peptide sequences 85 have been discovered since the publication of these in silico studies 86 2012; Udenigwe et al., 2013) . The aim of this study was to develop an in silico methodology 87 to predict the potential of various dietary proteins to act as precursors of DPP-IV inhibitory 88
peptides. This in silico approach consisted of a model taking into account the potency of 89 previously identified food protein-derived DPP-IV inhibitory peptides and also accounted for 90 overlapping amino acid residues within a given protein region shared among different DPP-91 IV inhibitory peptide sequences. The overall aim of this study was to develop a predictive 92 tool to assist in the choice of food protein substrate for the subsequent development of 93 hydrolysates potentially containing potent DPP-IV inhibitory peptides. 94
Materials and methods 95

Food protein-derived DPP-IV inhibitory peptides 96
Different DPP-IV inhibitory peptide sequences reported in the literature were considered 97 for the in silico analysis. The DPP-IV inhibitory peptide sequences and their half maximal 98 inhibitory concentration (IC 50 ) values which were included in this study are summarised in 99 Table 1 . Food protein sequences which have previously been identified as a source of DPP-100 IV inhibitory peptides using in vitro (Connolly et al., 2014; Harnedy & FitzGerald, 2013; 101 Hatanaka et al., 2012; Huang et al., 2012; Lacroix & Li-Chan, 2014a , 2014b Nongonierma & 102 FitzGerald, 2013a; Silveira et al., 2013; Tulipano et al., 2011; Velarde-Salcedo et al., 2013) , 103 in silico (Lacroix & Li-Chan, 2012; Udenigwe et al., 2013) or in vivo (Uchida et al., 2011; 104 Uenishi et al., 2012) approaches were considered in this study. Dietary proteins from plant 105 and animal sources were analysed. The mature (without the propeptide) protein sequences 106 (72) were obtained from UniProt using the ExPASy resource portal. The different proteins 107 analysed in this study together with their accession number are listed in Table 2 . 108
The following rules were applied when assessing the potential of dietary proteins to act as 109 a source of DPP-IV inhibitory peptides: 110 -only peptides with an IC 50 value < 2000 μM were taken into account in this study, other 111 DPP-IV inhibitory peptides with higher IC 50 values were not considered due to their 112 relatively low in vitro potency. This cut off value was chosen since three amino acids (Trp, 113 Met and Leu) have previously been shown to inhibit DPP-IV, however, their in vitro potency 114 was low as they displayed IC 50 values > 2000 μM (Nongonierma et al., 2013) . 115 -when specific peptide sequences have been reported with different IC 50 values, the 116 values reported in studies where the IC 50 for Diprotin A (the positive control for the DPP-IV 117 inhibition assay) was between 3-5 μM (Huang et al., 2012; Nongonierma & FitzGerald, 118 2013a; Silveira et al., 2013; Umezawa, Aoyagi, Ogawa, Naganawa, Hamada & Takeuchi, 119 1984) , were incorporated in the model. 120
Peptide sequence alignment was carried out using the Matlab Bioinformatics tool box 121 (version R2013b, MathWorks, Inc, Natick, MA, USA) for the 39 most potent DPP-IV 122 inhibitory peptides, i.e., peptides with an IC 50 value < 200 μM as listed in Table 1 . In 123 addition, sequence alignment of 58 peptides (Supplementary Table S1 ) with an IC 50 > 2000 124 μM or no DPP-IV inhibitory properties (Gallego et al., 2014; Hoffmann et al., 1995; 125 Nongonierma & FitzGerald, 2013c , 2013d Nongonierma et al., 2013; Silveira et al., 2013; 126 Uenishi et al., 2012) was also carried out. Visualisation of sequence alignments was used to 127 distinguish features in the primary sequence of the peptides which may be related to their 128 DPP-IV inhibitory properties. Protein alignment for κ-casein (CN) from different species 129 (bovine, human, ovine, caprine and bubaline) was also carried out to determine if the DPP-IV 130 inhibitory peptides were present within conserved regions in this protein molecule. 131
Identification of the presence of DPP-IV inhibitory peptides within different dietary 132 proteins 133
When a protein molecule is subjected to enzymatic hydrolysis, each amino acid residue 134 therein can theoretically only contribute to one specific peptide. Therefore, when several 135 DPP-IV inhibitory peptide sequences sharing at least one common amino acid residue have 136 been reported within a given region of a specific dietary protein, only the most potent DPP-137 IV inhibitory peptide was taken into account for its contribution to the overall DPP-IV 138 inhibitory potential of that protein. The DPP-IV inhibitory peptide sequences sharing 139 common amino residues in the 72 dietary proteins studied herein were identified using an in-140 house algorithm developed with Matlab. 141
The corrected number of DPP-IV inhibitory peptides (n i,corrected ) corresponded to the 142 occurrence of a given peptide i (n i ) less the occurrence of the most potent DPP-IV inhibitory 143 peptide(s) sharing at least one common amino acid residue with peptide i. For example, 144 within the peptides reported in Table 1 , the motif Ile-Pro or Ile-Pro-Ile was common within 145 the following peptides: Ile-Pro, Ile-Pro-Ala, Ile-Pro-Ala-Val-Phe, Ile-Pro-Ala-Val-Phe-Lys, 146
Ile-Pro-Ile, Ile-Pro-Ile-Gln-Tyr and Leu-Pro-Gln-Asn-Ile-Pro-Pro-Leu. The peptides reported 147
in Table 1 were mapped on the sequence of the individual milk proteins (Fig. 1) . Considering 148 bovine κ-CN by the way of example (Fig. 1) were considered in the in silico model whereas Ile-Pro-Ile-Gln-Tyr was not included. This 156 selection process was enacted in order to avoid considering the contribution of the same 157 amino acid residue or partial peptide sequence to the overall DPP-IV inhibitory properties 158 more than once during the in silico analysis. 159
Determination of a protein coverage (PC) value 160
The proportion of amino acid residues participating in DPP-IV inhibitory peptide 161 sequences with IC 50 values < 2000 μM ( 
Where x i is the length of the DPP-IV inhibitory peptide i (number of amino acid 170 residues); 171 n i,corrected is the corrected occurrence of peptide i in the dietary protein; 172 Y is the length (total number of amino acid residues) of the mature protein 173 (i.e., without the propeptide sequence). 174
175
When PC corrected was equal to PC, this indicated that there were no overlapping DPP-IV 176 inhibitory peptides within the protein sequence. 177
Determination of the DPP-IV inhibitory potency index (PI) 178
A DPP-IV inhibitory PI was calculated for different proteins taking into account the 179 potency (IC 50 value) of the DPP-IV inhibitory peptides evaluated therein using Matlab. The 180 PI (expressed in μM -1 g -1 ) of each protein was calculated using the following formula: 181 (Table 1 ). These sequences included Diprotin A and B (Umezawa et al., 1984) 195 and DPP-IV inhibitory peptides which have previously been identified in the sequences of a 196 wide range of food proteins including milk (Lacroix & Li-Chan, 2014a; Nongonierma & 197 FitzGerald, 2013a , 2013c , 2013d , 2014 Silveira et al., 2013; Tulipano et al., 2011; Uchida et 198 al., 2011; Uenishi et al., 2012) , rice (Hatanaka et al., 2012) , tuna cooking juice (Huang et al., 199 2012) along with porcine (Hsu et al., 2013) and salmon skin gelatin (Li-Chan et al., 2012) . elsewhere (Huang et al., 2012; Silveira et al., 2013; Umezawa et al., 1984) . 207
The peptides displayed a wide range of IC 50 values, from 3.5 to 1691.4 μM for Ile-Pro-Ile 208 and Met-Trp, respectively. Some of the DPP-IV inhibitory peptides selected herein share 209 common amino acid residues. Therefore, overlapping amino acids in dietary proteins were 210 considered in order to only take these sequences into account once in the in silico analysis. 
Occurrence of DPP-IV inhibitory peptides in dietary proteins 221
To date, most of the DPP-IV inhibitory peptides identified from dietary protein sources 222 come from milk proteins (Table 1) . However, this is probably related to the fact that most 223 research on dietary protein hydrolysates with DPP-IV inhibitory properties has been carried 224 out with milk proteins. This analysis showed that all the individual milk proteins contain 225 multiple peptide sequences with DPP-IV inhibitory properties. Furthermore, the DPP-IV 226 inhibitory peptides appear to be randomly distributed throughout the primary sequence of the 227 different milk proteins. Within milk proteins, the PC and the PC corrected with DPP-IV 228 inhibitory peptides with an IC 50 < 2000 μM ranged from 7.9 to 43.9 % for bovine serum 229 albumin (BSA) and α-La, respectively (Table 2) . 230
Specific peptide sequences which have previously been identified in milk proteins may 231 also be found in other dietary protein sources. This may be the case, in particular, for short 232 peptide sequences (di-, tri-and tetrapeptides). Therefore, the in silico approach described 233 herein was applied to a wide range of dietary proteins. The occurrence of DPP-IV inhibitory 234 peptides in the different dietary proteins was evaluated with the PC and the PC corrected analysis 235 (Table 2 ). The PC described the proportion of the protein consisting of DPP-IV inhibitory 236 peptides with an IC 50 < 2000 μM. Whereas PC corrected only considered the most potent DPP-237 IV inhibitory peptide in overlapping areas of the protein sequence. Among the proteins listed 238 in Table 2 , the highest PC was estimated for bovine α-La (43.9 %) and the lowest for bovine 239 myosin regulatory light chain 12B (1.2 %). The highest and lowest PC corrected values were also 240 found for the same proteins. Different numbers of unique sequences with DPP-IV inhibitory 241 activity were taken into account in the in silico model ( Table 2 ). The highest being for bovine 242 lactoferrin (18 peptides) and Atlantic salmon collagen Type XI α2 (18 peptides) and the 243 lowest being for bovine myosin regulatory light chain 12B (1 peptide). 244
DPP-IV inhibitory PI of dietary proteins 245
The DPP-IV inhibitory PI was calculated for each dietary protein ( Table 2 ). The highest 246 value for the PI was found for bovine κ-CN (17.89 10 -6 μM -1 g -1 ) and the lowest for bovine 247 myosin regulatory light chain 12B and chicken egg ovomucoid (0.13 10 -6 μM -1 g -1 ). Most 248 dietary proteins (90 %) had a PI < 5.00 10 -6 μM -1 g -1 . Proteins with a PI > 5.00 10
included bovine milk (κ-CN and α-La), canola (napin small chain), Palmaria palmata 250 (allophycocyanin α chain and phycoerythrin β subunit), chum salmon (type 1 collagen α2 251 chain), chicken egg (ovotransferrin), oat (avenin) and wheat (glutenin, low molecular weight 252 subunit 1D1) proteins. 253
The PC was equal to the PC corrected for 23 of the dietary proteins studied (Table 2) . When 254 the PC equals PC corrected , the protein does not present any overlapping DPP-IV inhibitory 255 peptides in its primary sequence. When PC corrected < PC, this indicates that the protein 256 contained overlapping DPP-IV inhibitory peptides. The difference between PC corrected and the 257 PC was the highest with bovine α-La, β-lactoglobulin (β-Lg), β-and κ-CN, with a difference 258 > 15%. 259
Bovine κ-CN had the highest PI, therefore, the in silico analysis was also applied to κ-CN 260 from different species including human, ovine, caprine and bubaline sources (Table 3 ). The 261 PI for ovine κ-CN was the highest (18.52 10 -6 μM -1 g -1 ) and the lowest was for human κ-CN 262 (2.11 10 -6 μM -1 g -1 ). These variations in the PI between species arise from the DPP-IV 263 inhibitory peptide sequences found within the different κ-CNs. In addition, ovine κ-CN 264 contained the highest number (11) of DPP-IV inhibitory peptides with an IC 50 < 2000 μM 265 while human κ-CN contained the lowest (6). Ovine κ-CN contained 2 highly potent (< 50 266 μM) DPP-IV inhibitors, Ile-Pro-Ile and Ile-Pro-Ala (IC 50 3.5 and 49 μM, respectively). 267
Interestingly, human κ-CN was the only κ-CN which does not contain Ile-Pro-Ile, Leu-Pro-268
Tyr-Pro-Tyr, Trp-Gln and His-Leu. 269
Protein alignment of κ-CN from the different species was carried out (Fig. 3) 
Discussion 277
Various studies have highlighted the potential of food protein-derived peptides to act as 278 antidiabetic components (Lacroix & Li-Chan, 2014b) . In this context, inhibition of DPP-IV 279 by food protein-derived peptides has been suggested as an avenue for the regulation of serum 280 glucose in vivo (Uchida et al., 2011; Uenishi et al., 2012) . Numerous peptide sequences 281 having DPP-IV inhibitory properties have been reported in the literature. However, it is still 282 not clear which structural/compositional parameters correlate with potent DPP-IV inhibitory 283
properties. Peptide length does not appear to govern DPP-IV inhibition as large peptides (> 284 10 amino acid residues) have been shown to be DPP-IV inhibitors (Velarde-Salcedo et al., 285 2013) . Some of these peptides were relatively potent (IC 50 value < 100 μM) DPP-IV 286 inhibitors (Huang et al., 2012; Lacroix & Li-Chan, 2014a; Uenishi et al., 2012) . Amino acid 287 composition is also not the primary component which would appear to govern DPP-IV 288 inhibitory properties as demonstrated by the differences in activity between reverse and 289 forward dipeptides (Hatanaka et al., 2012; Nongonierma & FitzGerald, 2013a , 2013d . showed that the peptides were not generally located in conserved regions of the protein. 331
Interestingly, it was found that ovine κ-CN had the highest PI. In contrast, human κ-CN had a 332 surprisingly low index (~ 9 times lower than that of ovine κ-CN). A recent study has shown 333 that at equivalent lactose content, a human milk meal was less insulinogenic than a bovine 334 milk meal when ingested by humans (Gunnerud, Holst, Östman & Björck, 2012) . However, 335 in this study, the human milk sample was tested at a lower protein level compared to the 336 bovine milk (3.5 and 16.8 g, respectively). Major differences between animal and human 337 milk exists in terms of their carbohydrate composition, notably, human milk contains nearly 338 twice as much lactose (7.5 g L -1 ) as bovine, caprine and bubaline milk (Fox, 2009 ). The high 339 lactose levels in human milk may help to counteract damage to vital organs of the neonate, 340 which may occur in the event of prolonged hypoglycaemia, a condition which is often 341 encountered with neonates (Adamkin, 2011). The high lactose content of human milk may 342 induce an increased insulin secretion in the post prandial phase. Therefore, it could be 343 hypothetised that regulation of insulin secretion through DPP-IV inhibition may not be as 344 critical with humans as compared with other species. This may explain the low PI of human 345 κ-CN compared to that of bovine, ovine and bubaline milk. 346
With the exception of porcine gelatin, it was found that several proteins (barley, rice, 347 amaranth, salmon, pig and Palmaria palamata) which were previously identified as dietary 348 sources of DPP-IV inhibitory peptides had a PI value > 4.00 10 -6 μM -1 g -1 (Table 2) (Table 1) . 363
The DPP-IV inhibition assay is affected by different parameters including the source of the 364 DPP-IV employed, its purity, enzyme activity, the synthetic substrate used, the temperature 365 and the enzyme to substrate ratio employed during the assay. Therefore, it is difficult to try to 366 standardise different values reported in the literature. In addition, the model is based on the 367 assumption that the most potent DPP-IV inhibitory peptide will be released from regions 368 containing overlapping peptide sequences. It may therefore lead to an overestimation of the 369 potential of a protein to act as a good starting substrate for DPP-IV inhibitory peptides. 370 However, the model is flexible and can build in discoveries of novel DPP-IV inhibitory 371 peptides or take into consideration the worst case scenario whereby the least potent peptide 372 would be released from protein regions containing overlapping DPP-IV inhibitory peptides. 373
This in silico approach could be considered as a starting point to identify dietary proteins 374 which are enriched in potent DPP-IV inhibitory peptides. To date, other in silico approaches 375 aiming to identify dietary proteins enriched in DPP-IV inhibitory peptides have not taken into 376 account the potency of previously identified DPP-IV inhibitory peptides and have considered 377 that the same amino acid from a dietary protein could participate in several DPP-IV 378 inhibitory peptide sequences. Evaluation of the DPP-IV inhibitory properties of enzymatic 379 hydrolysates of proteins predicted to have a high PI is needed in order to validate the model 380 presented herein. Ultimately, the peptides released will be governed by the nature of the 381 enzymatic preparation and the hydrolysis conditions employed during protein hydrolysis. 382
Conclusion 383
An in silico approach to evaluate the DPP-IV inhibitory potential of dietary proteins has 384 been developed. This model allowed for the identification of new dietary proteins which 385 contain potent DPP-IV inhibitory peptides. It takes into account both the potency of DPP-IV 386 inhibitory peptides and the fact that each amino acid from a dietary protein can only 387 participate once in a DPP-IV inhibitory peptide sequence. The model also incorporates the 388 latest DPP-IV inhibitory peptide sequences which have been discovered since previous in 389 silico studies in the area. In addition, peptide alignment approach was used herein to allow 390 for a better understanding of those features which are shared among relatively potent DPP-IV 391 inhibitory peptides (IC 50 < 200 μM). However the data presented herein needs to be validated 392 with in vitro enzymatic digestion of the individual substrates identified and the stability of the 393 peptides to gastrointestinal digestion also needs to be assessed. This work has highlighted a 394 new approach to predict the DPP-IV inhibitory potential of food protein-derived peptides and 395 to assess the potential of dietary proteins as a source for potent DPP-IV inhibitory peptides. 396
The strategy described herein could also be applied more broadly to other bioactive peptides 397 of relevance to human health. 398 LPQNIPPL from gouda-type cheese and its effect on plasma glucose in rats. 495
International Dairy Journal, 22, [24] [25] [26] [27] [28] [29] [30] Umezawa, H., Aoyagi, T., Ogawa, K., Naganawa, H., Hamada, M., & Takeuchi, T. (1984) . 497
Diprotins A and B, inhibitors of dipeptidyl aminopeptidase IV, produced by bacteria. 498
Journal of Antibiotics, 37, [422] [423] [424] [425] Velarde-Salcedo, A. J., Barrera-Pacheco, A., Lara-González, S., Montero-Morán, G. M., 500
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